In vitro culture medium influences the vaccine efficacy of Mycobacterium bovis BCG

Vaccine

Volumn 30, Issue 6, 2012, Pages 1038-1049

  Venkataswamy, Manjunatha M ^a   Goldberg, Michael F ^a   Baena, Andres ^a,b   Chan, John ^a   Jacobs, William R ^a   Porcelli, Steven A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Adaptive immunity; BCG; T cell; Tuberculosis

Indexed keywords

BCG VACCINE; CASPASE 3; CXCL1 CHEMOKINE; CYCLOOXYGENASE 2; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 17;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFICACY; ENZYME ACTIVATION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MALE; MIDDLEBROOK 7H9 MEDIUM; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAUTON MEDIUM; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TH17 CELL; VACCINE PRODUCTION;

ANIMALS; BCG VACCINE; CULTURE MEDIA; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS; TUBERCULOSIS, PULMONARY;

EID: 84856328414     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.044     Document Type: Article

References (42)

1. Oettinger T., Jorgensen M., Ladefoged A., Haslov K., Andersen P. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuberc Lung Dis 1999, 79(4):243-250.
2. Ritz N., Curtis N. Mapping the global use of different BCG vaccine strains. Tuberculosis (Edinb) 2009, 89(July (4)):248-251.
3. Fine P.E. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995, 346(November (8986)):1339-1345.
4. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. J Am Med Assoc 1994, 271(March (9)):698-702.
5. Russell D.G., Barry C.E., Flynn J.L. Tuberculosis: what we don't know can, and does, hurt us. Science 2010, 328(May (5980)):852-856.
6. Leung A.S., Tran V., Wu Z., Yu X., Alexander D.C., Gao G.F., et al. Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. BMC Genomics 2008, 9:413.
7. Brosch R., Gordon S.V., Garnier T., Eiglmeier K., Frigui W., Valenti P., et al. Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci USA 2007, 104(March (13)):5596-5601.
8. Bonah C. Packaging BCG: standardizing an anti-tuberculosis vaccine in interwar Europe. Sci Context 2008, 21(June (2)):279-310.
9. Eickhoff T.C. The current status of BCG immunization against tuberculosis. Annu Rev Med 1977, 28:411-423.
10. Florio W., Batoni G., Esin S., Bottai D., Maisetta G., Favilli F., et al. Influence of culture medium on the resistance and response of Mycobacterium bovis BCG to reactive nitrogen intermediates. Microbes Infect 2006, 8(February (2)):434-441.
11. Petricevich V.L., Ueda C., Alves R.C., da Silva M.A., Moreno C., Melo A.R., et al. A single strain of Mycobacterium bovis bacillus Calmette-Guerin (BCG) grown in two different media evokes distinct humoral immune responses in mice. Braz J Med Biol Res 2001, 34(January (1)):81-92.
12. Converse S.E., Cox J.S. A protein secretion pathway critical for Mycobacterium tuberculosis virulence is conserved and functional in Mycobacterium smegmatis. J Bacteriol 2005, 187(February (4)):1238-1245.
13. Hatfull G. Molecular genetics of Mycobacteria 2000, ASM Press.
14. Skinner P.S., Furney S.K., Jacobs M.R., Klopman G., Ellner J.J., Orme I.M. A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. Antimicrob Agents Chemother 1994, 38(November (11)):2557-2563.
15. Salem M.L., Al-Khami A.A., El-Naggar S.A., Diaz-Montero C.M., Chen Y., Cole D.J. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J Immunol 2010, 184(February (4)):1737-1747.
16. + T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood 2010, 115(March (12)):2397-2406.
17. Gan H., Lee J., Ren F., Chen M., Kornfeld H., Remold H.G. Mycobacterium tuberculosis blocks crosslinking of annexin-1 and apoptotic envelope formation on infected macrophages to maintain virulence. Nat Immunol 2008, 9(October (10)):1189-1197.
18. Hinchey J., Lee S., Jeon B.Y., Basaraba R.J., Venkataswamy M.M., Chen B., et al. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J Clin Invest 2007, 117(August (8)):2279-2288.
19. Chen M., Divangahi M., Gan H., Shin D.S., Hong S., Lee D.M., et al. Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 2008, 205(November (12)):2791-2801.
20. Cooper A.M., Khader S.A. The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis. Immunol Rev 2008, 226(December):191-204.
21. Flynn J.L., Goldstein M.M., Chan J., Triebold K.J., Pfeffer K., Lowenstein C.J., et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995, 2(June (6)):561-572.
22. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13(July (7)):843-850.
23. Torrado E, Cooper AM. IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev 2010;21(December (6)):455-62.
24. Behr M, Schurr E, Gros P. TB: screening for responses to a vile visitor. Cell 2010;140(March (5)):615-8.
25. Altare F., Durandy A., Lammas D., Emile J.F., Lamhamedi S., Le Deist F., et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998, 280(May (5368)):1432-1435.
26. Newport M.J., Huxley C.M., Huston S., Hawrylowicz C.M., Oostra B.A., Williamson R., et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996, 335(December (26)):1941-1949.
27. + T cells mediate IFN-gamma-independent control of Mycobacterium tuberculosis infection both in vitro and in vivo. J Immunol 2003, 171(November (9)):4689-4699.
28. Forbes E.K., Sander C., Ronan E.O., McShane H., Hill A.V., Beverley P.C., et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008, 181(October (7)):4955-4964.
29. Tchilian E.Z., Desel C., Forbes E.K., Bandermann S., Sander C.R., Hill A.V., et al. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis. Infect Immun 2009, 77(February (2)):622-631.
30. Sutherland J.S., Adetifa I.M., Hill P.C., Adegbola R.A., Ota M.O. Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease. Eur J Immunol 2009, 39(March (3)):723-729.
31. Hovav A.H., Mullerad J., Davidovitch L., Fishman Y., Bigi F., Cataldi A., et al. The Mycobacterium tuberculosis recombinant 27-kilodalton lipoprotein induces a strong Th1-type immune response deleterious to protection. Infect Immun 2003, 71(June (6)):3146-3154.
32. Delogu G., Brennan M.J. Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis. Infect Immun 2001, 69(September (9)):5606-5611.
33. Andersen P. Vaccine strategies against latent tuberculosis infection. Trends Microbiol 2007, 15(January (1)):7-13.
34. Comas I, Chakravartti J, Small PM, Galagan J, Niemann S, Kremer K, et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010;42(June (6)):498-503.
35. Young J.M., Adetifa I.M., Ota M.O., Sutherland J.S. Expanded polyfunctional T cell response to mycobacterial antigens in TB disease and contraction post-treatment. PLoS ONE 2010, 5(6):e11237.
36. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007, 8(April (4)):369-377.
37. Wozniak TM, Saunders BM, Ryan AA, Britton WJ. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect Immun 2010;78(October (10)):4187-94.
38. Okamoto Yoshida Y, Umemura M, Yahagi A, O'Brien RL, Ikuta K, Kishihara K, et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010;184(April (8)):4414-22.
39. Lotte A., Wasz-Hockert O., Poisson N., Dumitrescu N., Verron M., Couvet E. BCG complications. Estimates of the risks among vaccinated subjects and statistical analysis of their main characteristics. Adv Tuberc Res 1984, 21:107-193.
40. Guld J., Magnus K., Tolderlund K., Biering-Sorensen K., Edwards P.Q. Suppurative lymphadenitis following intradermal B.C.G. vaccination of the newborn; a preliminary report. Br Med J 1955, 2(October (4947)):1048-1054.
41. Lotte A., Wasz-Hockert O., Poisson N., Engbaek H., Landmann H., Quast U., et al. Second IUATLD study on complications induced by intradermal BCG-vaccination. Bull Int Union Tuberc Lung Dis 1988, 63(June (2)):47-59.
42. Corbett E.L., Watt C.J., Walker N., Maher D., Williams B.G., Raviglione M.C., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003, 163(May (9)):1009-1021.